270 related articles for article (PubMed ID: 34042040)
1. Immunotherapies for Parkinson's Disease: Progression of Clinical Development.
Teng JS; Ooi YY; Chye SM; Ling APK; Koh RY
CNS Neurol Disord Drug Targets; 2021; 20(9):802-813. PubMed ID: 34042040
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease.
Béné R; Antić S; Budisić M; Lisak M; Trkanjec Z; Demarin V; Podobnik-Sarkanji S
Acta Clin Croat; 2009 Sep; 48(3):377-80. PubMed ID: 20055267
[TBL] [Abstract][Full Text] [Related]
4. The understanding of Parkinson's disease through genetics and new therapies.
Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
[TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
6. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM; Gravel C; Lévesque M
J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
[TBL] [Abstract][Full Text] [Related]
7. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
[TBL] [Abstract][Full Text] [Related]
8. Targeting alpha-synuclein for the treatment of Parkinson's disease.
Rohn TT
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease: Autoimmunity and neuroinflammation.
De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
11. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
12. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
13. [Premotor diagnosis of Parkinson's disease].
Morales-Briceño H; Cervantes-Arriaga A; Rodríguez-Violante M
Gac Med Mex; 2011; 147(1):22-32. PubMed ID: 21412393
[TBL] [Abstract][Full Text] [Related]
14. Overview of Parkinson's disease.
Lew M
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935
[TBL] [Abstract][Full Text] [Related]
15. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Parkinson's disease: Current status and future directions.
Chatterjee D; Kordower JH
Neurobiol Dis; 2019 Dec; 132():104587. PubMed ID: 31454546
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
19. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
Schofield DJ; Irving L; Calo L; Bogstedt A; Rees G; Nuccitelli A; Narwal R; Petrone M; Roberts J; Brown L; Cusdin F; Dosanjh B; Lloyd C; Dobson C; Gurrell I; Fraser G; McFarlane M; Rockenstein E; Spencer B; Masliah E; Spillantini MG; Tan K; Billinton A; Vaughan T; Chessell I; Perkinton MS
Neurobiol Dis; 2019 Dec; 132():104582. PubMed ID: 31445162
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein, lipids and Parkinson's disease.
Ruipérez V; Darios F; Davletov B
Prog Lipid Res; 2010 Oct; 49(4):420-8. PubMed ID: 20580911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]